AR030026A1 - Nuevos derivados de acidos carboxilicos con anillo de pirimidina 5,6-sustituido, su uso para preparar medicamentos y combinaciones y preparados farmaceuticos que los comprenden - Google Patents

Nuevos derivados de acidos carboxilicos con anillo de pirimidina 5,6-sustituido, su uso para preparar medicamentos y combinaciones y preparados farmaceuticos que los comprenden

Info

Publication number: AR030026A1
Authority: AR; Argentina
Prior art keywords: alkyl; halogen; alkoxy; alkylthio; phenyl
Prior art date: 1999-07-20

Application number

ARP000103661A

Other languages

English (en)

Spanish (es)

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-20

Filing date

2000-07-17

Publication date

2003-08-13

2000-07-17 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2003-08-13 Publication of AR030026A1 publication Critical patent/AR030026A1/es

Links

239000003814 drug Substances 0.000 title abstract 2
239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 32
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 11
229910052736 halogen Inorganic materials 0.000 abstract 11
125000004414 alkyl thio group Chemical group 0.000 abstract 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 9
-1 pyrimidine ring carboxylic acid Chemical class 0.000 abstract 8
125000001188 haloalkyl group Chemical group 0.000 abstract 7
150000002367 halogens Chemical class 0.000 abstract 7
125000004438 haloalkoxy group Chemical group 0.000 abstract 6
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 6
125000004093 cyano group Chemical group *C#N 0.000 abstract 5
125000003342 alkenyl group Chemical group 0.000 abstract 4
125000000304 alkynyl group Chemical group 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 4
125000005843 halogen group Chemical group 0.000 abstract 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
229910052717 sulfur Inorganic materials 0.000 abstract 4
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 3
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 3
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 3
239000003112 inhibitor Substances 0.000 abstract 3
125000001624 naphthyl group Chemical group 0.000 abstract 3
229910052760 oxygen Inorganic materials 0.000 abstract 3
239000001301 oxygen Substances 0.000 abstract 3
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 3
239000011593 sulfur Substances 0.000 abstract 3
125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 2
125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 2
125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 2
102000002045 Endothelin Human genes 0.000 abstract 2
108050009340 Endothelin Proteins 0.000 abstract 2
102000003729 Neprilysin Human genes 0.000 abstract 2
108090000028 Neprilysin Proteins 0.000 abstract 2
125000003302 alkenyloxy group Chemical group 0.000 abstract 2
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
150000001768 cations Chemical class 0.000 abstract 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
101800000733 Angiotensin-2 Proteins 0.000 abstract 1
102400000345 Angiotensin-2 Human genes 0.000 abstract 1
229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
229910052783 alkali metal Inorganic materials 0.000 abstract 1
150000001340 alkali metals Chemical class 0.000 abstract 1
229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
150000001342 alkaline earth metals Chemical class 0.000 abstract 1
125000004450 alkenylene group Chemical group 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000005210 alkyl ammonium group Chemical group 0.000 abstract 1
125000005093 alkyl carbonyl alkyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000005133 alkynyloxy group Chemical group 0.000 abstract 1
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
229940030606 diuretics Drugs 0.000 abstract 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 1
FONOSWYYBCBQGN-UHFFFAOYSA-N ethylene dione Chemical group O=C=C=O FONOSWYYBCBQGN-UHFFFAOYSA-N 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
125000002883 imidazolyl group Chemical group 0.000 abstract 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
125000003226 pyrazolyl group Chemical group 0.000 abstract 1
125000000168 pyrrolyl group Chemical group 0.000 abstract 1
239000002461 renin inhibitor Substances 0.000 abstract 1
230000036454 renin-angiotensin system Effects 0.000 abstract 1
229940086526 renin-inhibitors Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1
150000003536 tetrazoles Chemical class 0.000 abstract 1
125000001425 triazolyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)

ARP000103661A 1999-07-20 2000-07-17 Nuevos derivados de acidos carboxilicos con anillo de pirimidina 5,6-sustituido, su uso para preparar medicamentos y combinaciones y preparados farmaceuticos que los comprenden AR030026A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19933164A DE19933164A1 (de)	1999-07-20	1999-07-20	Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten

Publications (1)

Publication Number	Publication Date
AR030026A1 true AR030026A1 (es)	2003-08-13

Family

ID=7914884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP000103661A AR030026A1 (es)	1999-07-20	2000-07-17	Nuevos derivados de acidos carboxilicos con anillo de pirimidina 5,6-sustituido, su uso para preparar medicamentos y combinaciones y preparados farmaceuticos que los comprenden

Country Status (21)

Country	Link
EP (1)	EP1196394A1 (cs)
JP (1)	JP2003505377A (cs)
KR (1)	KR20020019550A (cs)
CN (1)	CN1367778A (cs)
AR (1)	AR030026A1 (cs)
AU (1)	AU6561500A (cs)
BG (1)	BG106321A (cs)
BR (1)	BR0012592A (cs)
CA (1)	CA2379545A1 (cs)
CZ (1)	CZ2002190A3 (cs)
DE (1)	DE19933164A1 (cs)
HU (1)	HUP0202646A3 (cs)
IL (1)	IL147666A0 (cs)
MX (1)	MXPA02000616A (cs)
NO (1)	NO20020254L (cs)
PL (1)	PL353165A1 (cs)
SK (1)	SK772002A3 (cs)
TR (1)	TR200200622T2 (cs)
TW (1)	TW555749B (cs)
WO (1)	WO2001005771A1 (cs)
ZA (1)	ZA200200333B (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2462065T3 (es) *	2009-07-10	2014-05-22	Cadila Healthcare Limited	Proceso mejorado para la preparación de Ambrisentán e intermedios novedosos de este
CA2792473A1 (en)	2010-03-15	2011-09-22	Natco Pharma Limited	A process for the preparation of highly pure ambrisentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19636046A1 (de) *	1996-09-05	1998-03-12	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
WO1999023078A2 (de) *	1997-10-31	1999-05-14	Basf Aktiengesellschaft	Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten

1999
- 1999-07-20 DE DE19933164A patent/DE19933164A1/de not_active Withdrawn
2000
- 2000-07-05 PL PL00353165A patent/PL353165A1/xx not_active Application Discontinuation
- 2000-07-05 JP JP2001511432A patent/JP2003505377A/ja not_active Abandoned
- 2000-07-05 WO PCT/EP2000/006293 patent/WO2001005771A1/de not_active Ceased
- 2000-07-05 SK SK77-2002A patent/SK772002A3/sk unknown
- 2000-07-05 EP EP00953009A patent/EP1196394A1/de not_active Withdrawn
- 2000-07-05 BR BR0012592-0A patent/BR0012592A/pt not_active IP Right Cessation
- 2000-07-05 KR KR1020027000815A patent/KR20020019550A/ko not_active Ceased
- 2000-07-05 TR TR2002/00622T patent/TR200200622T2/xx unknown
- 2000-07-05 HU HU0202646A patent/HUP0202646A3/hu unknown
- 2000-07-05 CN CN00810533A patent/CN1367778A/zh active Pending
- 2000-07-05 AU AU65615/00A patent/AU6561500A/en not_active Abandoned
- 2000-07-05 CA CA002379545A patent/CA2379545A1/en not_active Abandoned
- 2000-07-05 MX MXPA02000616A patent/MXPA02000616A/es unknown
- 2000-07-05 IL IL14766600A patent/IL147666A0/xx unknown
- 2000-07-05 CZ CZ2002190A patent/CZ2002190A3/cs unknown
- 2000-07-13 TW TW089113992A patent/TW555749B/zh active
- 2000-07-17 AR ARP000103661A patent/AR030026A1/es unknown
2002
- 2002-01-15 ZA ZA200200333A patent/ZA200200333B/en unknown
- 2002-01-17 NO NO20020254A patent/NO20020254L/no not_active Application Discontinuation
- 2002-01-18 BG BG106321A patent/BG106321A/xx unknown

Also Published As

Publication number	Publication date
HUP0202646A3 (en)	2003-03-28
JP2003505377A (ja)	2003-02-12
KR20020019550A (ko)	2002-03-12
NO20020254D0 (no)	2002-01-17
IL147666A0 (en)	2002-08-14
AU6561500A (en)	2001-02-05
EP1196394A1 (de)	2002-04-17
BG106321A (en)	2002-08-30
CN1367778A (zh)	2002-09-04
NO20020254L (no)	2002-02-20
CA2379545A1 (en)	2001-01-25
TW555749B (en)	2003-10-01
MXPA02000616A (es)	2002-08-30
SK772002A3 (en)	2003-01-09
ZA200200333B (en)	2003-04-30
TR200200622T2 (cs)	2002-06-21
HUP0202646A2 (hu)	2003-02-28
DE19933164A1 (de)	2001-01-25
BR0012592A (pt)	2002-05-28
PL353165A1 (en)	2003-10-20
WO2001005771A1 (de)	2001-01-25
CZ2002190A3 (cs)	2003-08-13

Publication	Publication Date	Title
CY1118321T1 (el)	2017-06-28	Συστημα διαλυτων για βελτιωση της διαλυτοτητας των φαρμακευτικων παραγοντων
BG100016A (bg)	1996-04-30	Нiv протеазни инхибитори във фармацевтични комбинации за лечение на спин
BR0210504A (pt)	2004-05-18	Derivados de naftil-indol substituidos, atuantes como inibidores do inibidor tipo 1 (pai-1) do ativador de plasminogênio
AR037485A1 (es)	2004-11-17	Uso de un compuesto derivado de pirazol-triazina en la fabricacion de un medicamento, medicamento que comprende un compuesto derivado de pirazol-triazina, producto industrial y composicion farmaceutica
PE20240775A1 (es)	2024-04-17	Compuestos antivirales
EA200970047A1 (ru)	2009-04-28	Водные суспензии тмс278
NO20024177L (no)	2002-10-29	Farmasöytiske preparater inneholdende azetidinderivater, de nye azetidinderivater og deres fremstilling
AR057996A1 (es)	2008-01-09	Compuestos, composiciones pesticidas y metodo par combatir pestes
ECSP067076A (es)	2007-01-26	Derivados de pirimidina urea como inhibidores de la quinasa
UY28578A1 (es)	2005-06-30	Derivados de amida
BG98793A (bg)	1995-04-28	Нови производни на аминокиселините,методи за тяхното получаване и фармацевтични състави,съдържащи тези съединения
AR032467A1 (es)	2003-11-12	Derivados de piridina, procedimiento para prepararlos, el uso de dichos derivados para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
DE60319269D1 (de)	2008-04-03	Pharmazeutische verwendungen von 2-substituierten 4-heteroarylpyrimidinen
DE69919397D1 (de)	2004-09-16	Thrombin-inhibitoren
AR105893A1 (es)	2017-11-22	Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato
TR199701647A2 (xx)	1998-07-21	�kame edilmi� purin t�revleri,bunlar�n imalat usul�
ES2061462T3 (es)	1994-12-16	Compuestos cefemo, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
AR070573A1 (es)	2010-04-21	Derivados de 5,6 - bisaril -2- piridina - carboxamida, su preparacion, un medicamento y una composicion farmaceutica en base al compuesto, y la utilizacion del compuesto para la preparacion de un medicamento
ES2255190T3 (es)	2006-06-16	Compuestos indol 2,3-sustituidos como inhibidores de cox-2.
TR200102523T2 (tr)	2002-02-21	Alkenil ve alkinil içeren metaloproteaz inhibitörleri
DE60119368D1 (de)	2006-06-08	Zusammensetzung enthaltend einen angiotensin-ii-rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
AR030026A1 (es)	2003-08-13	Nuevos derivados de acidos carboxilicos con anillo de pirimidina 5,6-sustituido, su uso para preparar medicamentos y combinaciones y preparados farmaceuticos que los comprenden
BR0009674A (pt)	2002-01-15	Composto, droga, e, uso de composto
SE0002476D0 (sv)	2000-06-30	New compounds
AR030273A1 (es)	2003-08-20	Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina